Prior JC , Langsetmo L , Lentle BC , et al . Ten-year incident osteoporosis-related fractures in the population-based Canadian multicentre osteoporosis study-Comparing site and age-specific risks in women and men . Bone 2015 ; 71 : 237 - 43 .

Berglundh S , Malmgren L , Luthman H , et al . C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort . Osteoporos Int 2015 ; 26 : 727 - 35 .

Mitchell BD , Streeten EA . Clinical impact of recent genetic discoveries in osteoporosis . Appl Clin Genet 2013 ; 6 : 75 - 85 .

Lee SH , Lee SW , Ahn SH , et al . Multiple gene polymorphisms can improve prediction of nonvertebral fracture in postmenopausal women . J Bone Miner Res 2013 ; 28 : 2156 - 64 .

Otrock ZK , Mahfouz RA , Charafeddine KM , et al . Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis . Ann Hematol 2008 ; 87 : 947 - 8 .

Sai AJ , Gallagher JC , Fang X . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor-α genotypes . Menopause 2011 ; 18 : 1101 - 12 .

Kruk M , Ralston SH , Albagha OM . LRP5 polymorphisms and response to risedronate treatment in osteoporotic men . Calcif Tissue Int 2009 ; 84 : 171 - 9 .

Zhou PR , Liu HJ , Liao EY , et al . LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis . Pharmacogenomics 2014 ; 15 : 821 - 31 .

Olmos JM , Zarrabeitia MT , Hernández JL , et al . Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphos- phonates . Pharmacogenomics J 2012 ; 12 : 227 - 32 .

Favus MJ . Bisphosphonates for osteoporosis . NEJM 2010 ; 363 : 2027 - 35 .

Russell RG . Bisphosphonates: the first 40 years . Bone 2011 ; 49 : 2 - 19 .

Burnett-Bowie SM , Saag K , Sebba A . Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates . J Clin Endocrinol Metab 2009 ; 94 : 1097 - 103 .

Emkey R , Delmas PD , Bolognese M , et al . Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study . Clin Ther 2009 ; 31 : 751 - 61 .

Orwoll ES1 , Binkley NC , Lewiecki EM . Efficacy and safety of monthly ibandronate in men with low bone density . Bone 2010 ; 46 : 970 - 6 .

Tsubaki M , Komai M , Itoh T , et al . Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation . J Biomed Sci 2014 ; 21 : 10 .

Dudakovic A , Wiemer AJ , Lamb KM , et al . Inhibition of geranylgeranyl pyrophosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzyme . JPET 2008 ; 324 : 1028 - 36 .

Liu Y , Liu H , Li M , et al . Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis . Chin Med J 2014 ; 127 : 662 - 8 .

Chen SH , Lin SW , Lin SR , et al . Moiety-linkage map reveals selective nonbisphosphonate inhibitors of human geranylgeranyl diphosphate synthase . J Chem Inf Model 2013 ; 53 : 2299 - 311 .

Ericsson J , Greene JM , Carter KC , et al . Human geranyl- geranyl diphosphate synthase: isolation of the cDNA, chromosomal mapping and tissue expression . J Lipid Res 1998 ; 39 : 1731 - 9 .

Cummings SR , Bates D , Black DM . Clinical use of bone densitometry scientific review . JAMA 2002 ; 288 : 1889 - 97 .

Kanis JA , Melton LJ , Christiansen C , et al . The diagnosis of osteoporosis . J Bone Miner Res 1994 ; 9 : 1137 - 41 .

Kavanagh KL , Guo K , Dunford JE , et al . The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs . Proc Natl Acad Sci USA 2006 ; 103 : 7829 - 34 .

Tsubaki M , Kato C , Nishinobo M , et al . Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells . Cancer Sci 2008 ; 99 : 152 - 8 .

Ling Y , Li ZH , Miranda K , et al . The farnesyl-dipho-sphate/ geranylgeranyl-diphosphate synthase of toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates . J Biol Chem 2007 ; 282 : 30804 - 16 .

Fisher JE , Rogers MJ , Halasy JM , et al . Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro . Proc Natl Acad Sci USA 1999 ; 96 : 133 - 8 .

Coxon FP , Helfrich MH , Van’t Hof R , et al . Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298 . J Bone Miner Res 2000 ; 15 : 1467 - 76 .

Choi HJ , Choi JY , Cho SW . Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women . Yonsei Med J 2010 ; 51 : 231 - 8 .

Marini F , Brandi ML . Pharmacogenetics of osteoporosis: future perspectives . Calcif Tissue Int 2009 ; 84 : 337 - 47 .

Benford , HL , McGowan NW, Helfrich MH, et al. Visuali- zation of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro . Bone 2001 ; 28 : 465 - 73 .

Halasy-Nagy JM , Rodan GA , Reszka AA . Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apotosis . Bone 2001 ; 29 : 553 - 9 .

Ishijima M , Sakamoto Y , Yamanaka M , et al . Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women . Calcif Tissue Int 2009 ; 85 : 398 - 404 .